Cargando…
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Pancreatic adenocarcinoma (PAC) is one of the most deadly malignant neoplasms, and the efficacy of conventional cytotoxic chemotherapy is far from satisfactory. Recent research studies have revealed that immunosuppression and inflammation are associated with oncogenesis, as well as tumor development...
Autores principales: | Kimbara, Shiro, Kondo, Shunsuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011660/ https://www.ncbi.nlm.nih.gov/pubmed/27672267 http://dx.doi.org/10.3748/wjg.v22.i33.7440 |
Ejemplares similares
-
Clinical Development of Immune Checkpoint Inhibitors
por: Ito, Ayumu, et al.
Publicado: (2015) -
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2018) -
Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer
por: He, Li-Hong, et al.
Publicado: (2023) -
Immune Checkpoints: Therapeutic Targets for Pituitary Tumors
por: Nie, Ding, et al.
Publicado: (2021) -
Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)